Peptide Knowledge Base · GH-axis

GHRP-2: what it is, what the evidence says, and its real status

GHRP-6's tidier sibling, a bit more selective, still restricted and WADA-banned. Education only; the legal GH-axis answer is Sermorelin.

Can you actually get it?

Plain-English verdict: Education only.

Regulatory status: Expected to stay restricted.

How does GHRP-2 work?

A ghrelin-receptor agonist that releases growth hormone with somewhat less appetite stimulation than GHRP-6.

What it does — and what it does not do

What it does: Raises growth hormone; used historically in performance contexts.

What it does not do: It is not approved or available, and remains a restricted research compound.

How honest is the evidence?

Evidence grade D — Animal and lab evidence; human trials still to come.

older data; restricted; prolactin/cortisol effects milder than GHRP-6

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Long-term endocrine effects are poorly characterized.

WADA status: Banned (S2).

Who should not take it

WADA S2 banned; prolactin/cortisol effects; not characterized for safe human use.

Sources

GHRP-2 GH-secretagogue literature; FDA compounding restriction list

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.